Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Second Actemra Pivotal Trial Supports Novel IL-6 Inhibitor In Rheumatoid Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche expects two additional Phase III clinical trials evaluating tocilizumab to report later this year.

You may also be interested in...



Actemra OPTION Trial Shows Benefit In RA Patients In Combination With Methotrexate

Phase III trial, published in The Lancet, supports the use of Roche’s interleukin-6 inhibitor for rheumatoid arthritis.

Actemra OPTION Trial Shows Benefit In RA Patients In Combination With Methotrexate

Phase III trial, published in The Lancet, supports the use of Roche’s interleukin-6 inhibitor for rheumatoid arthritis.

Roche Files BLA For Rheumatoid Arthritis Therapy Actemra

The novel interleukin-6 receptor-inhibiting mAb has a projected September 2008 action date.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066284

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel